DEA Just Scheduled an Opioid Ten Times Stronger Than Fentanyl. Your Test Strip Won’t Catch It.

On July 1, the DEA filed a Federal Register notice (docket DEA-1665) placing four synthetic opioids into Schedule I on a temporary, emergency basis: cychlorphine — chemists call it N-propionitrile chlorphine, a tweaked version of the opioid chlorphine — along with spirochlorphine and two dichloro-desmethylchlorphine analogs. The notice states that HHS told DEA on April 10 that none of the four compounds has any approved or investigational drug application on file anywhere — no drugmaker, researcher, or hospital has a legal reason to be holding them.

Cychlorphine is the one that should have led the news cycle. It’s estimated at roughly ten times fentanyl’s potency, and it does not reliably trigger the fentanyl test strips that harm reduction programs hand out by the thousands, because those strips are built to bind fentanyl’s specific molecular shape, not a chemical cousin wearing a disguise. Instead, this notice landed the same day DEA scheduled 7-OH kratom derivatives, and the kratom fight ate every headline in sight.

The DEA just scheduled a fentanyl-strip-invisible opioid and almost nobody noticed, because a louder fight was happening one paragraph over.

That much is defensible. A compound this potent and this undetectable earns fast action. If you carry a strip because it’s the only thing standing between you and an unknown bag, you deserve to know it can miss something this dangerous — and you deserve a DEA that moves quickly when it does.

But Filter Mag’s Kastalia Medrano argues that DEA’s “abuse potential” standard — the legal bar required for emergency scheduling — is functionally undefined and applied inconsistently across the four compounds bundled into this single notice. Cychlorphine has roughly 230 documented detections nationally since 2022: a small number, but a real and climbing one. One of the other three analogs in DEA-1665 has just two known detections nationally and zero connected overdoses. Same emergency label, same lockout, applied to a compound found twice.

That distinction is not academic. Temporary Schedule I placement doesn’t just ban a drug — it closes the door on studying it. Once a compound is scheduled, a researcher needs a Schedule I registration, a slow and expensive process, before they can even characterize what it does in the body, and that lockout typically runs the full length of the temporary order, up to three years, before anyone can petition it back open. For a substance detected twice with no documented harm, that’s three years of foreclosed research bought at close to zero public safety benefit. For cychlorphine, it’s a trade worth making. Filing both under one emergency notice lets DEA claim urgency it hasn’t earned for half of what it just banned — and that’s the part worth being angry about, not the kratom headline that buried it.